Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Madrigal Pharmaceuticals (MDGL) Free Cash Flow (2019 - 2025)

Madrigal Pharmaceuticals (MDGL) has disclosed Free Cash Flow for 13 consecutive years, with -$133.1 million as the latest value for Q4 2025.

  • Quarterly Free Cash Flow fell 27.12% to -$133.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$190.0 million through Dec 2025, up 58.42% year-over-year, with the annual reading at -$190.0 million for FY2025, 58.42% up from the prior year.
  • Free Cash Flow for Q4 2025 was -$133.1 million at Madrigal Pharmaceuticals, down from $79.0 million in the prior quarter.
  • The five-year high for Free Cash Flow was $79.0 million in Q3 2025, with the low at -$149.5 million in Q1 2024.
  • Average Free Cash Flow over 5 years is -$69.1 million, with a median of -$63.4 million recorded in 2022.
  • The sharpest move saw Free Cash Flow tumbled 93.21% in 2021, then skyrocketed 216.57% in 2025.
  • Over 5 years, Free Cash Flow stood at -$48.2 million in 2021, then dropped by 21.55% to -$58.5 million in 2022, then plummeted by 38.3% to -$81.0 million in 2023, then decreased by 29.29% to -$104.7 million in 2024, then fell by 27.12% to -$133.1 million in 2025.
  • According to Business Quant data, Free Cash Flow over the past three periods came in at -$133.1 million, $79.0 million, and -$47.1 million for Q4 2025, Q3 2025, and Q2 2025 respectively.